Literature DB >> 6317738

Review of ulcer treatment: role of ranitidine.

E J Boyd, J A Wilson, K G Wormsley.   

Abstract

Ranitidine, given twice daily, increases the rate of healing of duodenal and gastric ulcers, irrespective of geographical location. The majority of ulcers (90-100%) heal after 2 months of treatment. Ulcers resistant to ranitidine treatment are uncommon and ranitidine heals ulcers resistant to other drugs, e.g. cimetidine. Healing of ulcers has been accompanied by an insignificant number of mild and reversible side effects. However, about 80% of healed ulcers recur within 1-2 years of stopping treatment. Continued treatment, with nocturnal administration of one half the healing dose of ranitidine, reduces the rate of recurrence during the first 12 months after healing to about 30% for duodenal ulcers and 20% for gastric ulcers. There is considerable variation within and between different countries. The recurrent ulcers seem to be clinically less severe than recurrences without maintenance treatment and are easily rehealed. If remission is maintained for more than 12 months during continued therapy, recurrence is uncommon. No significant adverse effects have been observed during maintenance treatment lasting nearly 3 years. The mechanisms whereby ranitidine heals ulcers and maintains remission are undefined but some possible processes are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6317738     DOI: 10.1097/00004836-198312001-00013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

Review 1.  Assessing the safety of drugs for the long-term treatment of peptic ulcers.

Authors:  K G Wormsley
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

2.  Comparison of different strategies for treatment of duodenal ulcer.

Authors:  A Sonnenberg
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

3.  Effect of 11R, 16, 16-trimethyl prostaglandin E2 on meal-stimulated gastric acid secretion in duodenal ulcer subjects.

Authors:  H J Lenz; S Brozinsky; M A Koss; D L Hogan; M L Scheinbaum; J I Isenberg
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Duodenal ulceration: review of 110 cases.

Authors:  M S Murphy; E J Eastham; M Jimenez; R Nelson; R H Jackson
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

5.  Ranitidine versus ranitidine and prazepam in the short-term treatment of duodenal ulcer--a double-blind controlled trial.

Authors:  C Hüscher; G Magni; A Salmi; S Bossini; C Felini; F Besozzi; D de Leo
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.